CITIUS ONCOLOGY, INC. — Form 8-K
Filed October 26, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Citius Oncology reported preliminary Q4 2026 (ended Sept 30, 2026) LYMPHIR unit sales to U.S. wholesalers of 792 units, up 120% from 360 units in Q3 2026. Institutional vial orders reached 950 during Q4 vs. 926 in Q3. As of the filing date, 54 institutions had ordered LYMPHIR compared to 44 as of August 14, 2026. CEO Leonard Mazur stated expanded commercial team achieved nationwide coverage in August and company is 'more than halfway' to goal of 100 priority institution formularies by end of calendar 2026. Figures are preliminary, unaudited, and subject to year-end audit completion expected in December 2026.
Why this rating
120% quarter-over-quarter shipment growth is material for a ~$5M market-cap biotech just 10 months post-launch; monetization trajectory validates commercialization strategy but remains early-stage with revenue not yet substantial relative to company size.
Price action (we called it positive)
before filing · preread $0.60 | at our read pending | +10 min pending | +30 min pending | +1 hr pending | +4 hrs pending |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from October 26, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.